Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Development of highly effective anti-mesothelin hYP218 Chimeric Antigen Receptor T cells with increased tumor infiltration and persistence for treating solid tumors

Raffit Hassan, Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku Miettinen, Nan Li, Ira Pastan, Mitchell Ho

Mol Cancer Ther molcanther.MCT-22-0073-A.2022.

DOI: https://doi.org/10.1158/1535-7163.MCT-22-0073

Published: 02 May 2022

View article

Includes: Supplementary data

Journal Articles

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Christine Alewine, Mehwish Iqra Ahmad, Cody J Peer, Seth Steinberg, William D Figg, Raffit Hassan, Ira Pastan

Mol Cancer Ther (2019) 18 (12_Supplement): A081.

DOI: https://doi.org/10.1158/1535-7163.TARG-19-A081

Published: 01 December 2019

View article

Journal Articles

Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer

Raffit Hassan, Ding Wang, John Wrangle, Anish Thomas, Angus Byars, Lianne Asschert, Rolando Atienza, Prabhu Rajagopalan, Annette Walter, Jun Zhang, Nenad Sarapa, Hedy Kindler

Mol Cancer Ther (2018) 17 (1_Supplement): A095.

DOI: https://doi.org/10.1158/1535-7163.TARG-17-A095

Published: 01 January 2018

View article

Journal Articles

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Ronit Mazor, Jingli Zhang, Laiman Xiang, Selamawit Addissie, Prince Awuah, Richard Beers, Raffit Hassan, Ira Pastan

Mol Cancer Ther (2015) 14 (12): 2789–2796.

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0532

Published: 06 December 2015

View article

Includes: Supplementary data

Journal Articles

Abstract B80: A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma.

Luana Calabro, Lee M. Krug, Alessandra DiPietro, Scott Antonia, Raffit Hassan, Rajesh Narwal, Paul Robbins, Dongyue Fu, Aiman Shalabi, Hesham Abdullah, Ramy Ibrahim, Hedy Kindler, Michele Maio

Mol Cancer Ther (2013) 12 (11_Supplement): B80.

DOI: https://doi.org/10.1158/1535-7163.TARG-13-B80

Published: 01 November 2013

View article

Journal Articles

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

John E. Weldon, Laiman Xiang, Jingli Zhang, Richard Beers, Dawn A. Walker, Masanori Onda, Raffit Hassan, Ira Pastan

Mol Cancer Ther (2013) 12 (1): 48–57.

DOI: https://doi.org/10.1158/1535-7163.MCT-12-0336

Published: 13 January 2013

View article

Includes: Supplementary data

Journal Articles

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Ronan J. Kelly, Elad Sharon, Ira Pastan, Raffit Hassan

Mol Cancer Ther (2012) 11 (3): 517–525.

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0454

Published: 06 March 2012

View article

NARROW

Development of highly effective anti-mesothelin hYP218 Chimeric Antigen Receptor T cells with increased tumor infiltration and persistence for treating solid tumors

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Abstract B80: A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma.

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Email alerts

AACR Journals

Development of highly effective anti-mesothelin hYP218 Chimeric Antigen Receptor T cells with increased tumor infiltration and persistence for treating solid tumors

Abstract A081: Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion

Abstract A095: Phase Ib study of anetumab ravtansine in combination with pemetrexed and cisplatin in patients with mesothelin-expressing epithelial mesothelioma or nonsquamous non-small cell lung cancer

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors

Abstract B80: A Phase II randomized, double-blind, placebo-controlled study of tremelimumab for second- and third-line treatment in patients with unresectable pleural or peritoneal mesothelioma.

A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only